Darbepoetin is named as an intervention in 2 current clinical trials in our India register. 1 is recruiting patients now. All registered phases are Not applicable. The lead sponsor is Institute of Liver and Biliary Sciences, India. The most-studied condition is Decompensated Cirrhosis.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.
NCT07002827 · ClinicalTrials.gov ↗ · Decompensated Liver Cirrhosis
|
Not applicable | Recruiting | Institute of Liver and Biliary Sciences, India | India |
|
National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis
NCT07131280 · Decompensated Cirrhosis
|
Not applicable | Not yet open | Institute of Liver and Biliary Sciences, India | India |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Institute of Liver and Biliary Sciences, India | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in India | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our India register name Darbepoetin as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Institute of Liver and Biliary Sciences, India. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Darbepoetin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Darbepoetin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Darbepoetin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.